Trial Profile
A Randomized, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Circumscribed scleroderma
- Focus Therapeutic Use
- Acronyms DupiMorph
- 14 Feb 2024 Status changed from recruiting to completed.
- 02 Nov 2022 Planned End Date changed from 1 May 2022 to 1 Jun 2025.
- 02 Nov 2022 Planned primary completion date changed from 1 May 2022 to 1 Aug 2024.